ACR 2022 Tweet by Catherine Sims, MD

What’s new to treat PsA? Let’s discuss anti-IL-17A, Izokibep #ACR22 @RheumNow

Abstract #0199
💪 Izokibep 40 v. 80 mg q2 weeks SQ v. placebo

💪 135 patients, 28 sites

💪 At 12 weeks, all patient reported outcomes and PsAID subdomains significantly improved (dose dependent)